Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial

Kyeong Ho Yun1*, Jae Young Cho1*, Seung Yul Lee1, Sang Jae Rhee1, Byeong Keuk Kim2, Myeong Ki Hong2, Yangsoo Jang2 and Seok Kyu Oh1 the TICO Investigators

1Departments of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, South Korea, 2Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea

Background: Ticagrelor monotherapy after 3-months dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI). However, the impact of this approach among the patient with diabetes remains unknown.

Methods: This was a sub-analysis of the Ticagrelor Monotherapy after 3 months in the Patients Treated with New Generation Sirolimus Eluting Stent for Acute Coronary Syndrome (TICO) trial. After successful PCI, the patients were randomly assigned to ticagrelor monotherapy after 3-months DAPT or to ticagrelor-based 12-months DAPT. We compared ischemic events and bleeding events between the patients with diabetes and without diabetes for 12 months. Ischemic events were defined as death, myocardial infarction, ischemic stroke, transient ischemic attack, stent thrombosis, and any revascularizations. Bleeding events were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria and Bleeding Academic Research Consortium (BARC) definition.

Results: Between August 2015 and October 2018, 3,056 patients were enrolled in the TICO trial, of which 835 (27.3%) had diabetes mellitus. Diabetes mellitus was associated with all evaluated ischemic and bleeding events. No significant differences in any ischemic events were observed in patients with diabetes between ticagrelor monotherapy after 3-months DAPT and ticagrelor-based 12-months DAPT (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.45–1.52, p = 0.540). In patients with diabetes, the overall incidence of bleeding complications during the 12-months follow-up period did not differ between the two treatment groups (HR 0.83, 95% CI 1.48–1.43, p = 0.505). However, ticagrelor monotherapy was significantly reduced both any TIMI bleeding and BARC three or five bleeding events in diabetes patients in the 3-months landmark analysis, after 3-months DAPT period (HR 0.20, 95% CI 0.07–0.59, p = 0.003).

Conclusion: In diabetic patients, ticagrelor monotherapy showed a lower incidence of bleeding complications after 3-months DAPT period, without increasing ischemic
INTRODUCTION

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor for 12 months is a standard therapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation (Levine et al., 2016; Valgimigli et al., 2018). The improved clinical performances of DES have reduced the risk of stent thrombosis; however, potent antiplatelet agents can increase the risk of bleeding complications. Therefore, determining the optimal duration of DAPT is especially important to prevent both ischemic and bleeding complications (Capodanno et al., 2015). Recently, short duration of DAPT, followed by P2Y12 inhibitor monotherapy, was shown to provide an optimal risk-benefit balance (Vranckx et al., 2018; Mehran et al., 2019; Kim et al., 2020). Ticagrelor Monotherapy after 3 months in the Patients Treated with New Generation Sirolimus Eluting Stent for Acute Coronary Syndrome (TICO) trial demonstrated that ticagrelor monotherapy after 3-months DAPT showed 34% reduction of net adverse events compared with 12-months DAPT with aspirin and ticagrelor, mainly reduction of bleeding events (Kim et al., 2020). However, additional studies remain necessary to evaluate several specific subgroups that have high ischemic or bleeding risks.

Diabetes mellitus is an important risk factor of both ischemic and bleeding complications. Pooled randomized trials showed diabetes was an independent predictor of major adverse cardiac events, cardiac death, and myocardial infarction (MI) after PCI (Kedhi et al., 2014). In the Platelet Inhibition and Patient Outcomes (PLATO) study, diabetic patients with ACS had a higher bleeding risk than non-diabetic patients in both clopidogrel and ticagrelor group (James et al., 2010). Therefore, the effect of antiplatelet strategy on the ischemic and bleeding events may differ between the patients with diabetes and without diabetes after PCI. This study investigated ischemic and bleeding events in the TICO trial according to diabetes mellitus status. We evaluated the impact of diabetes on the effect of two antiplatelet strategy, ticagrelor monotherapy after 3-months DAPT and 12-months DAPT with aspirin and ticagrelor.

METHODS

Study Population and Design

This is a sub-study of the TICO trial (clinicaltrials.gov identifier: NCT02494895). TICO trial was an investigator-initiated, multicenter, randomized, open-label trial conducted across 38 centers in South Korea. The rationale and detailed design have been previously published (Kim et al., 2019). In brief, total 3,056 patients with acute coronary syndrome (ACS) were randomly assigned to ticagrelor monotherapy after 3-months DAPT or to ticagrelor-based 12-months DAPT after successful percutaneous coronary intervention (PCI) with ultrathin biodegradable polymer sirolimus-eluting stents (Orsiro; Biotronik AG). All DAPT treatment composed a combination of aspirin and ticagrelor. Randomization sequence was computer generated and stratified according to diabetes status and ST-elevation myocardial infarction (MI). Key exclusion criteria included the increased risk of bleeding associated with prior hemorrhagic stroke, traumatic brain injury or brain surgery within the past 6 months, internal bleeding within the past 6 weeks, need of oral anticoagulation therapy, and anemia (hemoglobin ≤8 g/dl).

After a 3-months DAPT treatment consisting of ticagrelor and aspirin, the aspirin was discontinued for the ticagrelor monotherapy group and continued in the 12-months DAPT group. The collection of each participant’s current medication and adverse or end point-related events is performed at baseline and during 3, 6, 9, and 12 months of follow-up after PCI. Patients were categorized as diabetic if they received active treatment with insulin, an oral antidiabetic medication, or were treated through diet management.

Endpoints

The outcomes of present study included any ischemic and bleeding complications within 12 months of PCI. The TICO trial defined major adverse cardiac and cerebrovascular events as death, MI, stent thrombosis, stroke, or target vessel revascularization (TVR). Additionally, transient ischemic attack, ischemic stroke, and non-TV were analyzed as ischemic complications in this study according to Academic Research Consortium (Lansky et al., 2017; Garcia-Garcia et al., 2018). Bleeding complications were defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria and the Bleeding Academic Research Consortium (BARC) definition (Mehran et al., 2011). Endpoint detection and adjudication were obtained as previously outlined (Kim et al., 2020).

Statistical Analyses

Patient characteristics were compared by diabetes status using independent Student’s t-test or the Mann–Whitney U test in continuous variables and using a χ² test or Fisher’s exact test in categorical variables. Kaplan–Meier estimates and log-rank test were used to determine the cumulative incidences of the ischemic and bleeding events. Hazard ratio (HR) and 95% confidence interval (CI) were generated, using Cox proportional hazards models. To determine the effect of diabetes on the outcomes, following covariates were used for adjusting: age, gender, body mass index, hypertension, dyslipidemia, and ejection fraction. Patients without endpoints between randomization and 12 months were censored at the time of death, last contact date in cases with lost to follow-up or withdrew consent, or 365 days,
whichever came first. Treatment effects were estimated according to presence or absence of diabetes with interaction terms in a Cox proportional hazard model. Because the same treatment was given to both groups during the first 3 months, pre-specified 3-months landmark analyses were performed, after excluding the patients who experienced adverse events within this period. Analyses of both ischemic and bleeding events were performed using the intention-to-treat cohort. All statistical analyses were performed using R version 4.0.2. (The R foundation for Statistical Computing, Vienna, Austria). All

### TABLE 1 | Baseline clinical characteristics.

|                          | Diabetes (n = 835) | No diabetes (n = 2,221) | p value |
|--------------------------|--------------------|-------------------------|---------|
| Age (years)              | 63.3 ± 10.5        | 60.0 ± 10.7             | <0.001  |
| Male (%)                 | 612 (73.3)         | 1816 (81.8)             | <0.001  |
| Body mass index (kg/m²)  | 25.1 ± 3.4         | 24.9 ± 3.2              | 0.154   |
| Hypertension (%)         | 570 (68.3)         | 971 (43.7)              | <0.001  |
| Dyslipidemia (%)         | 535 (64.1)         | 1,311 (59.0)            | 0.011   |
| Current smoker (%)       | 266 (31.9)         | 876 (39.4)              | <0.001  |
| Previous stroke (%)      | 62 (7.4)           | 64 (2.9)                | <0.001  |
| Myocardial infarction (%)| 534 (64.0)         | 1,596 (71.9)            | <0.001  |
| Ejection fraction (%)    | 53.9 ± 12.6        | 54.8 ± 11.8             | 0.082   |
| Hemoglobin A1c (%)       | 5.7 ± 1.6          | 5.9 ± 1.0               | <0.001  |
| eGFR (mL/min/1.73m²)     | 71.2 ± 25.8        | 78.8 ± 22.2             | <0.001  |
| 12-months DPAT group     | 417 (49.9)         | 1,112 (50.1)            | 0.950   |

**Angiographic and procedural findings**

- **Culprit lesion (%)**
  - Left main: 27 (3.2) vs 53 (2.4)
p_value = 0.093
- **Left anterior descending**
  - 399 (47.8) vs 1,129 (50.8)
p_value = 0.380
- **Left circumflex**
  - 130 (15.6) vs 380 (17.1)
- **Right coronary artery**
  - 279 (33.4) vs 659 (29.7)
p_value = 0.001
- **Multi-vessel disease (%)**
  - 536 (64.2) vs 1,167 (52.5)
p_value = 0.001
- **Femoral approach (%)**
  - 369 (44.2) vs 989 (44.5)
p_value = 0.001
- **Stent number per patient**
  - 1.42 ± 0.72 vs 1.35 ± 0.65
  - p_value = 0.023
- **Stent diameter (mm)**
  - 3.10 ± 0.45 vs 3.16 ± 0.45
  - p_value = 0.001
- **Total stent length (mm)**
  - 36.8 ± 21.7 vs 34.0 ± 20.1
  - p_value = 0.001

**Discharge medication**

- **ACEI/ARB (%)**
  - 570 (68.3) vs 1,449 (65.2)
p_value = 0.116
- **Beta blocker (%)**
  - 548 (65.6) vs 1,468 (66.1)
p_value = 0.808
- **CCB (%)**
  - 114 (13.7) vs 283 (12.7)
p_value = 0.506
- **Statin (%)**
  - 819 (98.1) vs 2,174 (97.9)
p_value = 0.729

DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
p-values are two-sided, and a p-value lower than 0.05 was regarded as statistically significant.

RESULTS

Between August 2015 and October 2018, 3,056 patients were enrolled in the TICO trial, of which 835 (27.3%) had diabetes mellitus. Among diabetic patients, 82 (9.8%) patients were treated with insulin. The drug adherence and cross-over rates were similar between the two treatment strategy groups (Figure 1). Table 1 presents the baseline characteristics of patients, according to diabetic status. Diabetic patients presented worse clinical characteristics than nondiabetic patients. Patients with diabetes were older, more likely to report being current smokers, and had higher incidences of hypertension, dyslipidemia, and multivessel disease than nondiabetic patients. Medications other than aspirin, and procedures were well matched between the randomized treatment groups.

The effect of diabetes mellitus on all evaluated ischemic and bleeding events showed in Table 2 and Figure 2. Diabetic patients experienced a higher incidence of bleeding complications (6.3% vs. 3.7%, p = 0.002). Additionally, diabetic patients showed a higher incidence of all ischemic events, extended definitions in this study, than nondiabetic patients (5.0% vs. 2.9%, p = 0.004). No significant difference was found in any ischemic or bleeding events according to insulin treatment or baseline HbA1c levels (Table 3).

No significant differences in any ischemic events were observed in patients with diabetes between ticagrelor monotherapy after 3-months DAPT and ticagrelor-based 12-months DAPT (HR 0.83, 95% CI 0.45–1.52, p = 0.540) (Table 4). The incidence of death, MI, stroke, and any revascularizations was similar between ticagrelor monotherapy after 3-months DAPT and ticagrelor-based 12-months DAPT in both patients with diabetes and without diabetes. The 3-months landmark analysis showed similar incidence of ischemic complications during 3–12 months between the two treatment strategies (Figure 3). In the overall trial population, there was no significant interaction between diabetes status and treatment group with respect to ischemic events.

In diabetic patients, the overall incidences of bleeding events during the 12-months follow-up period did not differ between the two treatment groups (HR 0.83, 95% CI 1.48–1.43,
TABLE 3 | Outcomes in patients with diabetes.

|                          | Ticagrelor monotherapy | Ticagrelor-based DAPT | HR (95% CI)    | p value | p value (interaction) |
|--------------------------|------------------------|-----------------------|----------------|---------|----------------------|
| All-cause mortality      |                        |                       |                |         |                      |
| Insulin                  | 0/42 (0.0)             | 4/40 (10.0)           |                | 0.052*  | 0.996                |
| No insulin               | 8/376 (2.1)            | 10/377 (2.7)          | 0.81 (0.32-2.04) | 0.649   |                      |
| HbA1c >7.0%              | 3/159 (1.9)            | 8/166 (4.8)           | 0.52 (0.13-2.08) | 0.356   |                      |
| HbA1c ≤ 7.0%             | 0/132 (0.0)            | 0/121 (0.0)           |                | 1.000*  |                      |
| Major adverse cardiac and cerebrovascular events |                        |                       |                |         |                      |
| Insulin                  | 0/42 (0.0)             | 5/40 (12.5)           |                | 0.024*  | 0.997                |
| No insulin               | 13/376 (3.5)           | 16/377 (4.2)          | 0.82 (0.40-1.71) | 0.599   |                      |
| HbA1c >7.0%              | 4/159 (2.5)            | 8/166 (4.8)           | 0.52 (0.16-1.72) | 0.283   | 0.997                |
| HbA1c ≤ 7.0%             | 3/132 (2.3)            | 1/121 (0.8)           | 2.8 (0.29-26.95) | 0.372   |                      |
| Any ischemic events      |                        |                       |                |         |                      |
| Insulin                  | 1/42 (2.4)             | 6/40 (15.0)           | 0.14 (0.02-1.19) | 0.072   | 0.075                |
| No insulin               | 18/376 (4.8)           | 17/377 (4.5)          | 1.08 (0.56-2.09) | 0.827   |                      |
| HbA1c >7.0%              | 8/159 (5.0)            | 8/166 (4.8)           | 1.04 (0.59-2.78) | 0.933   | 0.075                |
| HbA1c ≤ 7.0%             | 5/132 (3.8)            | 1/121 (0.8)           | 4.7 (0.55-40.26) | 0.158   |                      |
| TIMI major bleeding      |                        |                       |                |         |                      |
| Insulin                  | 1/42 (2.4)             | 2/40 (5.0)            | 0.44 (0.04-4.84) | 0.501   | 0.730                |
| No insulin               | 11/376 (2.9)           | 16/377 (4.2)          | 0.70 (0.32-1.51) | 0.361   |                      |
| HbA1c >7.0%              | 7/159 (4.4)            | 5/166 (3.0)           | 1.49 (0.47-4.70) | 0.494   | 0.730                |
| HbA1c ≤ 7.0%             | 1/132 (0.8)            | 4/121 (3.3)           | 0.23 (0.03-2.04) | 0.186   |                      |
| All TIMI bleeding        |                        |                       |                |         |                      |
| Insulin                  | 3/42 (7.1)             | 6/40 (15.0)           | 0.44 (0.11-1.77) | 0.247   | 0.341                |
| No insulin               | 21/376 (5.6)           | 23/377 (6.1)          | 0.93 (0.52-1.68) | 0.810   |                      |
| HbA1c >7.0%              | 14/159 (8.8)           | 9/166 (5.4)           | 1.68 (0.73-3.89) | 0.222   | 0.341                |
| HbA1c ≤ 7.0%             | 2/132 (1.5)            | 8/121 (6.6)           | 0.23 (0.05-1.06) | 0.059   |                      |

Major adverse cardiac and cerebrovascular events (MACE) indicated composite of death, myocardial infarction, stent thrombosis, stroke, and target vessel revascularization (TVR). Any ischemic events indicated transient ischemic attack and non-TVR in addition to MACE.

*Fisher’s exact test.

p = 0.505 (Table 5). However, ticagrelor-based 12-months DAPT increased bleeding complications in the 3-months landmark analysis in both patients with diabetes and without diabetes (log-rank p = 0.0011 in patients with diabetes; p = 0.018 in patients without diabetes, Figure 4). Ticagrelor monotherapy was significantly reduced both TIMI major or minor bleeding events and BARC 3 or 5 bleeding events in diabetes patients after 3-months DAPT period compared with 12-months DAPT (HR 0.20, 95% CI 0.07–0.59, p = 0.003 by Cox proportional hazed regression analysis) (Figures 4A,C). In the overall population, interaction testing between diabetes status and treatment group for bleeding events was non-significant.

**DISCUSSION**

The key findings from this TICO sub-analysis include (1) ticagrelor-based 12-months DAPT did not reduced ischemic events in patients with diabetes compared with ticagrelor monotherapy after 3 months of DAPT, (2) ticagrelor monotherapy showed 80% reduction in the incidence of both any TIMI bleeding and BARC three or five bleeding after 3-months DAPT period in the patients with diabetes, and (3) the effect of ticagrelor monotherapy after 12-months DAPT on ischemic or bleeding events was not affected by diabetes status. Actually, ticagrelor monotherapy showed lower incidence of bleeding complications without increasing ischemic complications during 3–12 months irrespective of presence or absence of diabetes mellitus.

Because bleeding risks increase with prolonged DAPT, several studies have explored methods to shorten DAPT duration. The 6-months vs. 12-months or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome (SMART-DATE) trial reported that short DAPT less than 6 months showed increased risk of MI compared with 12-months DAPT in patients with ACS (Hahn et al., 2018). The TICO trial tested a strategy in which aspirin use was discontinued while continuing ticagrelor in patients with ACS (Kim et al., 2020). As a result, ticagrelor monotherapy after 3-months of DAPT significantly reduced composite outcomes compared with ticagrelor-based 12-months DAPT, reducing the risk of major bleeding, without increasing the risk of major adverse cardio-cerebrovascular events. However, studies about the effects of P2Y12 monotherapy on high risk patients such as diabetes, chronic kidney disease, or underwent complex intervention, and studies using various endpoint including minor events remains uncertain.

Diabetes mellitus is a major risk factor of atherosclerosis, disease progression, and restenosis after DES implantation (The BARI investigators, 1997; Van Belle et al., 2002; Bangalore et al., 2012). In diabetic patients, increased platelet activity and adhesion have been observed, resulting in a higher incidence of cardiovascular events and the reduced
antithrombotic efficacy of treatments based on aspirin and clopidogrel, compared with nondiabetic patients (Jung et al., 2015; Santilli et al., 2015). A meta-analysis showed that, although prolonged DAPT had no significant impacts on the rates of mortality, MI, and stroke, short DAPT (<6 months) followed by aspirin monotherapy was associated with a significant increase in the rate of stent thrombosis in diabetic patients compared with nondiabetic patients (Gargiulo et al., 2016; Sharma et al., 2018). Because of the prothrombotic state associated with diabetes, the evaluation of

### TABLE 4 | Ischemic events according to treatment group in patients with and without diabetes.

|                          | Ticagrelor monotherapy | Ticagrelor-based DAPT | HR (95%CI)          | p value | p value (interaction) |
|--------------------------|------------------------|-----------------------|---------------------|---------|----------------------|
| Death                    |                        |                       |                     |         |                      |
| Diabetes                 | 8/418 (1.9)            | 14/417 (3.4)          | 0.57 (0.24–1.36)    | 0.204   | 0.491                |
| No diabetes              | 8/1,109 (0.7)          | 9/1,112 (0.8)         | 0.90 (0.35–2.32)    | 0.819   |                      |
| Cardiac death            |                        |                       |                     |         |                      |
| Diabetes                 | 5/418 (1.2)            | 8/417 (1.9)           | 0.62 (0.20–1.91)    | 0.408   | 0.835                |
| No diabetes              | 2/1,109 (0.2)          | 4/1,112 (0.4)         | 0.50 (0.09–2.74)    | 0.426   |                      |
| Myocardial infarction    |                        |                       |                     |         |                      |
| Diabetes                 | 5/418 (1.2)            | 5/417 (1.2)           | 1.0 (0.29–3.46)     | 0.997   | 0.154                |
| No diabetes              | 1/1,109 (0.1)          | 6/1,112 (0.5)         | 0.17 (0.02–1.39)    | 0.098   |                      |
| Stent thrombosis         |                        |                       |                     |         |                      |
| Diabetes                 | 4/418 (1.0)            | 3/417 (0.7)           | 1.33 (0.30–5.93)    | 0.710   | 0.774                |
| No diabetes              | 2/1,109 (0.2)          | 1/1,112 (0.1)         | 2.0 (0.18–22.14)    | 0.569   |                      |
| TIA                      |                        |                       |                     |         |                      |
| Diabetes                 | 3/418 (0.7)            | 2/417 (0.5)           | 1.50 (0.25–8.95)    | 0.659   | 0.998                |
| No diabetes              | 0/1,109 (0.0)          | 3/1,112 (0.3)         | 0.250               | 0.250   |                      |
| Ischemic stroke          |                        |                       |                     |         |                      |
| Diabetes                 | 0/418 (0.0)            | 1/417 (0.2)           | 0.499               | 0.499   | 0.998                |
| No diabetes              | 5/1,109 (0.5)          | 8/1,112 (0.7)         | 0.63 (0.21–1.92)    | 0.414   |                      |
| TVR                      |                        |                       |                     |         |                      |
| Diabetes                 | 2/418 (0.5)            | 2/417 (0.5)           | 0.99 (0.14–7.05)    | 0.994   | 0.812                |
| No diabetes              | 6/1,109 (0.5)          | 8/1,112 (0.7)         | 0.76 (0.26–2.18)    | 0.604   |                      |
| Non-TVR                  |                        |                       |                     |         |                      |
| Diabetes                 | 3/418 (0.7)            | 0/417 (0.0)           | 0.249               | 0.249   | 0.997                |
| No diabetes              | 9/1,109 (0.8)          | 6/1,112 (0.5)         | 1.51 (0.54–4.23)    | 0.438   |                      |
| Any revascularization    |                        |                       |                     |         |                      |
| Diabetes                 | 5/418 (1.2)            | 2/417 (0.5)           | 2.50 (0.49–12.88)   | 0.274   | 0.288                |
| No diabetes              | 13/1,109 (1.2)         | 14/1,112 (1.3)        | 0.94 (0.44–1.99)    | 0.862   |                      |
| Any ischemic events      |                        |                       |                     |         |                      |
| Diabetes                 | 19/418 (4.5)           | 23/417 (5.5)          | 0.83 (0.45–1.52)    | 0.540   | 0.645                |
| No diabetes              | 26/1,109 (2.3)         | 38/1,112 (3.4)        | 0.69 (0.42–1.13)    | 0.138   |                      |

TIA, transient ischemic attack; TVR, target vessel revascularization.  
*aFisher’s exact test.

FIGURE 3 | Landmark analysis of ischemic events at 3 months. Between 3 and 12 months, the hazard ratio of ticagrelor monotherapy was 0.72 (95% CI 0.32–1.61) in diabetes, 0.69 (0.38–1.26) in no diabetes.
the efficacy of antiplatelet monotherapy after 3-months DAPT compared to 12-months DAPT with aspirin and a P2Y12 inhibitor for among patients with diabetes is of major importance. Actually, diabetes is considered to an indicator that a patient will benefit from prolonged DAPT strategy when calculated DAPT scores (Yeh et al., 2016). Recent evidence has indicated that aspirin therapy is insufficient to prevent newly developed serious cardiovascular events and may, instead, cause major bleeding events during the primary prevention era (ASCEND Study Collaborative Group, 2018). Therefore, aspirin alone is considered an insufficient treatment for ischemic events in diabetic patients.

The present study demonstrated that ticagrelor monotherapy did not increase ischemic events including stent thrombosis, and was not associated with bleeding risks in diabetic patients. To date, three randomized trials have examined ticagrelor monotherapy (Vranckx et al., 2018; Mehran et al., 2019; Kim et al., 2020). Although the study design and endpoints were different, GLOBAL LEADERS trial and Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention (TWILIGHT) trial both showed similar incidences of major cardiovascular events between the ticagrelor monotherapy group and the DAPT group among diabetic patients. The sub-analysis of TWILIGHT trial demonstrated that ticagrelor monotherapy showed 66% reduction of BARC 3 or 5 bleeding without increased incidence of ischemic events in patients with diabetes, although we used more extended definition of ischemic complications than the original TICO study. Moreover, we showed that even among diabetic patients, the discontinuation of aspirin after short-duration DAPT could prevent bleeding complications.

This study has several limitations. First, this study represents a subanlysis and was not designed to test the efficacy or safety of ticagrelor monotherapy in diabetic patients. Second, the statistical power of the TICO trial was calculated by estimating the occurrence of a composite outcome. The comparisons of each individual outcome, especially adverse cardiovascular and cerebrovascular events, could be underpowered. Third, we did not investigate the incidence of minor bleeding events such as BARC 1 or 2 bleeding. TICO study designed to evaluate net clinical effects. Study committee discussed whether importance of each ischemic and bleeding events were similar, and decided to exclude minor bleeding events. Fourth, pathophysiologic parameters, such as platelet reactivity, were not measured. The incidence of high on-treatment platelet reactivity might be higher in diabetic patients than in nondiabetic patients. However, our randomization strategy stratified by diabetes status and ST-elevation MI. Finally, it should be cautious to apply the results of this study to non-Asians or patients receiving drug-eluting stents other than Orsiro stents.

In conclusion, ticagrelor monotherapy showed a lower incidence of bleeding complications after 3-months DAPT period, without increasing ischemic complications, compared with ticagrelor-based 12-months DAPT in diabetic patients.

### Table 5: Bleeding events according to treatment group in patients with and without diabetes.

|                            | Ticagrelor monotherapy | Ticagrelor-based DAPT | HR (95%CI) | p value | p value (interaction) |
|---------------------------|------------------------|-----------------------|------------|---------|----------------------|
| **Fatal bleeding**        |                        |                       |            |         |                      |
| Diabetes                  | 0/418 (0.0)            | 1/417 (0.2)           | 0.499*     | 1.000   |                      |
| No diabetes               | 0/1,109 (0.0)          | 1/1,112 (0.1)         | 1.000*     |         |                      |
| **BARC 3A bleeding**      |                        |                       |            |         |                      |
| Diabetes                  | 10/418 (2.4)           | 9/417 (2.2)           | 1.11 (0.45-2.74) | 0.818   | 0.244                |
| No diabetes               | 15/1,109 (1.4)         | 26/1,112 (2.3)        | 0.58 (0.31-1.09) | 0.090   |                      |
| **BARC 3B bleeding**      |                        |                       |            |         |                      |
| Diabetes                  | 12/418 (2.9)           | 17/417 (4.1)          | 0.71 (0.34-1.49) | 0.364   | 0.489                |
| No diabetes               | 13/1,109 (1.2)         | 26/1,112 (2.3)        | 0.5 (0.26-0.97) | 0.041   |                      |
| **BARC 3C bleeding**      |                        |                       |            |         |                      |
| Diabetes                  | 2/418 (0.5)            | 2/417 (0.5)           | 0.99 (0.14-7.03) | 0.993   | 0.993                |
| No diabetes               | 1/1,109 (0.1)          | 1/1,112 (0.1)         | 1.0 (0.06-16.06) | 0.997   |                      |
| **BARC 3 or 5 bleeding**  |                        |                       |            |         |                      |
| Diabetes                  | 24/418 (5.7)           | 29/417 (7.0)          | 0.83 (0.48-1.43) | 0.505   | 0.219                |
| No diabetes               | 29/1,109 (0.8)         | 54/1,112 (4.9)        | 0.54 (0.34-0.84) | 0.007   |                      |
| **TIMI major bleeding**   |                        |                       |            |         |                      |
| Diabetes                  | 12/418 (2.9)           | 18/417 (4.3)          | 0.67 (0.32-1.39) | 0.281   | 0.513                |
| No diabetes               | 13/1,109 (1.2)         | 27/1,112 (2.4)        | 0.48 (0.25-0.94) | 0.031   |                      |
| **TIMI minor bleeding**   |                        |                       |            |         |                      |
| Diabetes                  | 12/418 (2.9)           | 11/417 (2.6)          | 1.09 (0.48-2.47) | 0.838   | 0.245                |
| No diabetes               | 16/1,109 (1.4)         | 27/1,112 (2.4)        | 0.59 (0.32-1.10) | 0.098   |                      |
| **All TIMI bleeding**     |                        |                       |            |         |                      |
| Diabetes                  | 24/418 (5.7)           | 29/417 (7.0)          | 0.83 (0.48-1.43) | 0.505   | 0.219                |
| No diabetes               | 29/1,109 (0.8)         | 54/1,112 (4.9)        | 0.54 (0.34-0.84) | 0.007   |                      |

**BARC, Bleeding Academic Research Consortium; TIMI, Thrombolysis in Myocardial Infarction.**

*Fisher’s exact test.
DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by institutional review board at each hospital. The patients provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

KY and JC study design and interpretation of results. SR, SO, B-KK, M-KH, and YJ data collection. KY, JC, and S-YL: data analysis. SR and B-KK validation. JC and SO supervision. KY preparation of manuscript. KY, JC, and S-YL manuscript review and editing. All authors contributed to the article and approved the submitted version.

REFERENCES

Angiolillo, D. J., Baber, U., Sartori, S., Briguori, C., Dangas, G., Cohen, D. J., et al. (2020). Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. 75, 2403–2413. doi:10.1016/j.jacc.2020.03.008
Bangalore, S., Kumar, S., Fusaro, M., Amoroso, N., Kirtane, A. J., Byrne, R. A., et al. (2012). Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 345, e5170, doi:10.1136/bmj.e5170

ASCEND Study Collaborative GroupBowman, L., Bowman, L., Matham, M., Wallendszus, K., Stevens, W., Buck, G., et al. (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529–1539. doi:10.1056/NEJMoa1804988
Capodanno, D., Gargiulo, G., Buccheri, S., Giacoppo, D., Capranzano, P., and Tamburino, C. (2015). Meta-analyses of dual antiplatelet therapy following drug-eluting stent implantation: do bleeding and stent thrombosis weigh similar on mortality?. J. Am. Coll. Cardiol. 66, 1639–1640. doi:10.1016/j.jacc.2015.05.085
García-García, H. M., McFadden, E. P., Farb, A., Mehran, R., Stone, G. W., Spertus, J., et al. (2018). Standardized end point definitions for coronary intervention
